<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774097</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-SPH-12-0785</org_study_id>
    <secondary_id>UM1HL087318-06</secondary_id>
    <nct_id>NCT01774097</nct_id>
  </id_info>
  <brief_title>Patients With Intermittent Claudication Injected With ALDH Bright Cells</brief_title>
  <acronym>PACE</acronym>
  <official_title>Clinical and MR Imaging Assessments in Patients With Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aldagen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if aldehyde dehydrogenase bright (ALDHbr) cells
      taken from a patient's bone marrow can be placed safely, via intramuscular injections, into
      their affected calf and lower thigh muscles and improve blood flow and/or peak walking time
      in patients experiencing pain associated with blocked blood vessels in the leg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral Artery Disease (PAD) occurs when arteries in the arms and legs (most often the
      legs) become narrowed by plaque. Because of this plaque, patients with PAD are also at
      increased risk for heart attacks and strokes. Those with PAD often have intermittent
      claudication (blockage of blood vessels in the leg). This blockage decreases blood flow to
      the leg muscles, which can cause pain in one or both legs during exercise (such as during
      walking). Intermittent means the pain comes and goes. Because PAD interferes with
      circulation, worsening of this condition can increase pain in the leg; sometimes even during
      periods of rest.

      Bone marrow contains special stem cells that may promote blood vessel growth, prevent cell
      death, and transform themselves into a number of tissues including new muscle. There is a
      small subpopulation of bone marrow mononuclear cells, called aldehyde dehydrogenase-bright
      (ALDHbr) cells, that is highly enriched in these types of stem cells. The enzyme in ALDHbr
      cells responds to damage signals and may play an important role in tissue repair.

      In this study we investigate the safety and efficacy of bone marrow derived stem cells with
      particular characteristics in PAD patients with intermittent claudication and explore new
      end-points to evaluate therapeutic effects using novel MRI imaging modalities as well as
      traditional endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Walking Time (PWT)</measure>
    <time_frame>Assessed at baseline and 6 months</time_frame>
    <description>The placebo adjusted average change over time in the maximum time (in minutes) walked by a patient on a treadmill under standardized conditions. The patient continues the test until walking can no longer be tolerated because of claudication symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Collateral Count (Via Contrast Enhanced-MR)</measure>
    <time_frame>Assessed at baseline and 6 months</time_frame>
    <description>The placebo adjusted average change in the number of collateral vessels over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Hyperemic Popliteal Flow (Phase Contrast MRA)</measure>
    <time_frame>Assessed at baseline and 6 months</time_frame>
    <description>The placebo adjusted average change in peak hyperemic popliteal flow (mL/s) over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Capillary Perfusion</measure>
    <time_frame>Assessed at baseline and 6 months</time_frame>
    <description>The placebo adjusted average change in capillary perfusion over time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-exercise Ankle-Brachial Index (ABI)</measure>
    <time_frame>Assessed as a trajectory (baseline, 3mos, and 6 mos)</time_frame>
    <description>ABI is the ratio of the blood pressure at the ankle to the blood pressure of the upper arm. Pre-exercise ABI is collected routinely with the patient supine immediately prior to a treadmill test. This measure represents the placebo adjusted average change over time in arm and pedal (ankle) blood pressure. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-exercise Ankle-Brachial Index (ABI)</measure>
    <time_frame>Assessed as a trajectory (baseline, 3mos, and 6 mos)</time_frame>
    <description>ABI is the ratio of the blood pressure at the ankle to the blood pressure of the upper arm. Post-exercise ABI is collected routinely with the patient supine immediately following a treadmill test. This measure represents the placebo adjusted average change over time in arm and pedal (ankle) blood pressure. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Claudication Onset Time (COT)</measure>
    <time_frame>Assessed as a trajectory (baseline, 3mos, and 6 mos)</time_frame>
    <description>Claudication Onset Time (COT) is the walking time at which patients first experience leg pain during a treadmill test. The measure represents placebo adjusted average change over time (in minutes) in the time walked by a patient on a treadmill under standardized conditions before the onset of claudication symptoms, regardless of whether this is manifested or characterized as muscle pain, ache, cramp, numbness or fatigue. This does not include joint pain or other pain not associated with claudication. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Walking Time (PWT)</measure>
    <time_frame>Assessed at baseline and 3 months</time_frame>
    <description>The average change in maximum time (in minutes) walked by a patient on a treadmill under standardized conditions. The patient continues the test until walking can no longer be tolerated because of claudication symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Artery Questionnaire (PAQ)</measure>
    <time_frame>Assessed as a trajectory (baseline, 1mos, 3mos, and 6 mos)</time_frame>
    <description>The Peripheral Artery Questionnaire (PAQ) assesses subjective physical limitations, leg symptoms, social function, treatment satisfaction, and quality of life. It is administered as a self report. Higher scores are indicative of better outcome. The summary scores is compiled by taking the mean of five subscales generated from the original questions. Range: Minimum score is 11.1, maximum 85. The measure represents placebo adjusted average change in Peripheral Artery Questionnaire (PAQ) summary score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire (WIQ)-Walking Distance Score</measure>
    <time_frame>Assessed as a trajectory (baseline, 1mos, 3mos, and 6 mos)</time_frame>
    <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0.2, maximum 100. The measure represents the placebo adjusted average change in WIQ walking distance score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire (WIQ)- Walking Speed Score</measure>
    <time_frame>Assessed as a trajectory (baseline, 1mos, 3mos, and 6 mos)</time_frame>
    <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0, maximum 87. The measure represents the placebo adjusted average change in WIQ walking speed score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire (WIQ)-Ability to Climb Stairs Score</measure>
    <time_frame>Assessed as a trajectory (baseline, 1mos, 3mos, and 6 mos)</time_frame>
    <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0, maximum 100. The measure represents the placebo adjusted average change in WIQ ability to climb stairs score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>ALD-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALD-301 via intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo (vehicle)via intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD-301</intervention_name>
    <description>Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh</description>
    <arm_group_label>ALD-301</arm_group_label>
    <other_name>ALDH Bright Cells</other_name>
    <other_name>ALDHbr</other_name>
    <other_name>Aldehyde dehydrogenase-bright cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (vehicle)</intervention_name>
    <description>Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
    <arm_group_label>Placebo (vehicle)</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Vehicle</other_name>
    <other_name>HSA</other_name>
    <other_name>Human Serum Albumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with atherosclerotic peripheral artery disease with classic claudication
             (exercise-induced pain, cramps, fatigue, or other equivalent discomfort involving
             large muscle groups of the leg(s) that is consistently relieved by rest) or atypical
             leg pain (exertional leg pain that does not begin at rest or does not resolve
             consistently with rest) as defined by the San Diego Claudication Questionnaire.

          2. Age ≥40 years

          3. Resting ankle-brachial index &lt;0.90 or a resting toe-brachial index of &lt;0.70 at
             baseline testing

          4. Presence of significant stenosis or occlusion of infrainguinal arteries including the
             superficial femoral artery, popliteal artery and/or infrapopliteal arteries as
             determined by: Duplex ultrasound imaging (occlusion or focal doubling of peak systolic
             velocity of one or more affected segments) OR lower extremity computed Tomography
             Angiography (CTA) OR lower extremity magnetic resonance angiography (MRA) OR lower
             extremity catheter-based contrast arteriography. Each of these noninvasive and
             invasive anatomic assessments will identify patients with at least a 50% stenosis in
             the affected segment.

        Exclusion Criteria:

          1. Presence of any musculoskeletal disease, cardiac or pulmonary disease, or neurological
             disease that limits the patient's ability to walk to fulfill protocol requirements
             (claudication must be the consistent primary exercise limitation)

          2. Inability to complete treadmill testing per protocol requirements.

          3. Ability to walk for more than 12 minutes on the treadmill during treadmill testing.

          4. Patients who identify both legs as equivocally symptomatic or alternate between
             symptomatic legs on the baseline treadmill tests.

          5. Patients with critical limb ischemia (ischemic rest pain or ischemia-related non
             healing wounds or tissue loss (Rutherford categories 4-6).

          6. Recent (&lt;3 months) infrainguinal revascularization (surgery or endovascular
             revascularization) or revascularization planned during study period

          7. Patients with a patent infrainguinal bypass graft in the index limb, with or without
             evidence of a hemodynamically significant stenosis or other defect (kinking,
             pseudoaneurysm, or fistula). Patients with an occluded infrainguinal bypass graft or a
             patent aortobifemoral or femoral-femoral bypass graft are NOT excluded.

          8. Patients with &gt;2+ lower extremity pitting edema

          9. Patients with myelodysplastic syndrome (MDS)

         10. Patients who are pregnant or lactating, planning to become pregnant in the next 12
             months, or are unwilling to use acceptable forms of birth control during study
             participation.

         11. Congestive Heart Failure hospitalization within the last 1 month prior to enrollment

         12. Acute coronary syndrome in the last 1 month prior to enrollment

         13. Human Immunodeficiency Virus positive, active Hepatitis B Virus or Hepatitis C Virus
             Disease

         14. History of cancer within the last 5 years, except basal cell skin carcinoma

         15. Any bleeding diathesis defined as an International Normalized Ratio ≥ 2.0 (off
             anticoagulation therapy) or history of platelet count less than 100,000 or hemophilia

         16. Contraindication to magnetic resonance imaging (MRI) (including knee/tibial/fibular
             replacement hardware in the index leg) or known allergy to MRI contrast media

         17. Chronic kidney disease [effective Glomerular Filtration Rate &lt;30 by modification of
             diet in renal disease (MDRD) or Mayo or Cockcroft-Gault formula]

         18. Uncontrolled diabetes [Hemoglobin A1C (HbA1C)&gt;8.5]

         19. Planned change to (initiate or terminate) active involvement in a supervised exercise
             program (e.g., with a trainer, exercise protocol, and goals, such as in a peripheral
             arterial disease, cardiac or pulmonary rehabilitation program) during study
             participation

         20. Plans to change medical therapy during the duration of the study, (i.e. patients who
             use cilostazol should remain on a stable dose for four weeks prior to enrollment and
             should not change doses for the 6 months of the study duration.) As always, cilostazol
             can be discontinued if new heart failure or intolerance occurs during study
             participation.

         21. Any condition requiring immunosuppressant medications (e.g., for treatment of organ
             transplants, psoriasis, Crohn's disease, alopecia areata).

         22. History of inflammatory or progressively fibrotic conditions (e.g. rheumatoid
             arthritis, systemic lupus erythematosis, vasculitic disorders, idiopathic pulmonary
             fibrosis, retroperitoneal fibrosis).

         23. Patients with any untreated stenosis &gt; 70% of the distal aorta, common iliac, or
             external iliac arteries by CT, Angiography or MRI imaging will be excluded from
             enrollment (patients with previously successfully revascularized inflow stenoses may
             enroll in PACE). Subjects who were screen failures for a flow-limiting proximal lesion
             may be rescreened 3 months after successful angioplasty/stenting.

         24. Inability to provide written informed consent due to cognitive or language barriers
             (interpreter permitted)

         25. Concurrent enrollment in another clinical interventional investigative trial.

         26. Presence of any clinical condition that in the opinion of the principal Investigator
             or the sponsor makes the patient not suitable to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Simari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Cell Therapy Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine (Falk Cardiovascular Research Center)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida-Department of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami-Interdisciplinary Stem Cell Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Health Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Center for Vascular Biology and Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical and Translational Science Institute at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cctrn.org</url>
    <description>Cardiovascular Cell Therapy Research Network</description>
  </link>
  <link>
    <url>http://www.nhlbi.nih.gov/</url>
    <description>National Heart, Lung, and Blood Institute</description>
  </link>
  <reference>
    <citation>Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006 Mar 21;113(11):e463-654. Review.</citation>
    <PMID>16549646</PMID>
  </reference>
  <reference>
    <citation>Perin EC, Silva G, Gahremanpour A, Canales J, Zheng Y, Cabreira-Hansen MG, Mendelsohn F, Chronos N, Haley R, Willerson JT, Annex BH. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv. 2011 Dec 1;78(7):1060-7. doi: 10.1002/ccd.23066. Epub 2011 May 18.</citation>
    <PMID>21594960</PMID>
  </reference>
  <reference>
    <citation>Perin EC, Murphy M, Cooke JP, Moyé L, Henry TD, Bettencourt J, Gahremanpour A, Leeper N, Anderson RD, Hiatt WR, Lima JA, Venkatesh B, Sayre SL, Vojvodic RW, Taylor DA, Ebert RF, Hirsch AT; Cardiovascular Cell Therapy Research Network. Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. Am Heart J. 2014 Nov;168(5):667-73. doi: 10.1016/j.ahj.2014.07.021. Epub 2014 Jul 30.</citation>
    <PMID>25440794</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <results_first_submitted>January 3, 2017</results_first_submitted>
  <results_first_submitted_qc>March 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Dr Lemuel A Moye III</investigator_full_name>
    <investigator_title>Professor - School of Public Health</investigator_title>
  </responsible_party>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Intermittent Claudication</keyword>
  <keyword>Autologous Stem Cells</keyword>
  <keyword>ALDH cells</keyword>
  <keyword>Claudicants</keyword>
  <keyword>PAD</keyword>
  <keyword>Peak Walking Time</keyword>
  <keyword>MRI</keyword>
  <keyword>Vascular Flow</keyword>
  <keyword>Anatomy</keyword>
  <keyword>Perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intermittent Claudication</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment took place at seven Network centers and their associated satellite facilities between 6/13/2013 and 12/8/2015. The main centers are located in Texas, Florida (2 locations), Minnesota, Kentucky, Indiana, and California. Study brochures, patient informational DVDs, and clinicaltrials.gov were among the tools used for recruitment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ALDHbr</title>
          <description>Participants will receive ALDHbr via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr in the index calf and posterior, lower thigh</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Vehicle)</title>
          <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Information for 4 participants is not available due to patient withdrawal from the study.</population>
      <group_list>
        <group group_id="B1">
          <title>ALDHbr</title>
          <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Vehicle)</title>
          <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="8.6"/>
                    <measurement group_id="B2" value="66.2" spread="8.7"/>
                    <measurement group_id="B3" value="66.2" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Walking Time (PWT)</title>
        <description>The placebo adjusted average change over time in the maximum time (in minutes) walked by a patient on a treadmill under standardized conditions. The patient continues the test until walking can no longer be tolerated because of claudication symptoms.</description>
        <time_frame>Assessed at baseline and 6 months</time_frame>
        <population>Participants who had available analyzable baseline and 6 month treadmill test results.</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Walking Time (PWT)</title>
          <description>The placebo adjusted average change over time in the maximum time (in minutes) walked by a patient on a treadmill under standardized conditions. The patient continues the test until walking can no longer be tolerated because of claudication symptoms.</description>
          <population>Participants who had available analyzable baseline and 6 month treadmill test results.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="3.9"/>
                    <measurement group_id="O2" value="1.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.238</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leg Collateral Count (Via Contrast Enhanced-MR)</title>
        <description>The placebo adjusted average change in the number of collateral vessels over time.</description>
        <time_frame>Assessed at baseline and 6 months</time_frame>
        <population>Participants who had available analyzable baseline and 6 month MRI imaging</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Collateral Count (Via Contrast Enhanced-MR)</title>
          <description>The placebo adjusted average change in the number of collateral vessels over time.</description>
          <population>Participants who had available analyzable baseline and 6 month MRI imaging</population>
          <units>vessel count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.7"/>
                    <measurement group_id="O2" value="0.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.116</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Hyperemic Popliteal Flow (Phase Contrast MRA)</title>
        <description>The placebo adjusted average change in peak hyperemic popliteal flow (mL/s) over time.</description>
        <time_frame>Assessed at baseline and 6 months</time_frame>
        <population>Participants who had available analyzable baseline and 6 month MRI imaging</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Hyperemic Popliteal Flow (Phase Contrast MRA)</title>
          <description>The placebo adjusted average change in peak hyperemic popliteal flow (mL/s) over time.</description>
          <population>Participants who had available analyzable baseline and 6 month MRI imaging</population>
          <units>ml/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.5"/>
                    <measurement group_id="O2" value="0.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Capillary Perfusion</title>
        <description>The placebo adjusted average change in capillary perfusion over time.</description>
        <time_frame>Assessed at baseline and 6 months</time_frame>
        <population>Participants with available analyzable MRI imaging at baseline and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Capillary Perfusion</title>
          <description>The placebo adjusted average change in capillary perfusion over time.</description>
          <population>Participants with available analyzable MRI imaging at baseline and 6 months</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="2.40"/>
                    <measurement group_id="O2" value="-0.25" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.752</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.26</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-exercise Ankle-Brachial Index (ABI)</title>
        <description>ABI is the ratio of the blood pressure at the ankle to the blood pressure of the upper arm. Pre-exercise ABI is collected routinely with the patient supine immediately prior to a treadmill test. This measure represents the placebo adjusted average change over time in arm and pedal (ankle) blood pressure. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
        <time_frame>Assessed as a trajectory (baseline, 3mos, and 6 mos)</time_frame>
        <population>Participants with available analyzable ABI data at baseline, 3 months, and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-exercise Ankle-Brachial Index (ABI)</title>
          <description>ABI is the ratio of the blood pressure at the ankle to the blood pressure of the upper arm. Pre-exercise ABI is collected routinely with the patient supine immediately prior to a treadmill test. This measure represents the placebo adjusted average change over time in arm and pedal (ankle) blood pressure. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
          <population>Participants with available analyzable ABI data at baseline, 3 months, and 6 months</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.17"/>
                    <measurement group_id="O2" value="0.64" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.871</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>interaction term</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-exercise Ankle-Brachial Index (ABI)</title>
        <description>ABI is the ratio of the blood pressure at the ankle to the blood pressure of the upper arm. Post-exercise ABI is collected routinely with the patient supine immediately following a treadmill test. This measure represents the placebo adjusted average change over time in arm and pedal (ankle) blood pressure. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
        <time_frame>Assessed as a trajectory (baseline, 3mos, and 6 mos)</time_frame>
        <population>Participants with available analyzable ABI at baseline, 3 months, and 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Post-exercise Ankle-Brachial Index (ABI)</title>
          <description>ABI is the ratio of the blood pressure at the ankle to the blood pressure of the upper arm. Post-exercise ABI is collected routinely with the patient supine immediately following a treadmill test. This measure represents the placebo adjusted average change over time in arm and pedal (ankle) blood pressure. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
          <population>Participants with available analyzable ABI at baseline, 3 months, and 6 months</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.15"/>
                    <measurement group_id="O2" value="0.34" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.256</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>interaction term</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Claudication Onset Time (COT)</title>
        <description>Claudication Onset Time (COT) is the walking time at which patients first experience leg pain during a treadmill test. The measure represents placebo adjusted average change over time (in minutes) in the time walked by a patient on a treadmill under standardized conditions before the onset of claudication symptoms, regardless of whether this is manifested or characterized as muscle pain, ache, cramp, numbness or fatigue. This does not include joint pain or other pain not associated with claudication. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
        <time_frame>Assessed as a trajectory (baseline, 3mos, and 6 mos)</time_frame>
        <population>Participants who had available analyzable baseline, 3 month, and 6 month treadmill test results.</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Claudication Onset Time (COT)</title>
          <description>Claudication Onset Time (COT) is the walking time at which patients first experience leg pain during a treadmill test. The measure represents placebo adjusted average change over time (in minutes) in the time walked by a patient on a treadmill under standardized conditions before the onset of claudication symptoms, regardless of whether this is manifested or characterized as muscle pain, ache, cramp, numbness or fatigue. This does not include joint pain or other pain not associated with claudication. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
          <population>Participants who had available analyzable baseline, 3 month, and 6 month treadmill test results.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.9"/>
                    <measurement group_id="O2" value="2.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <method>Regression, Linear</method>
            <param_type>interaction term</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Walking Time (PWT)</title>
        <description>The average change in maximum time (in minutes) walked by a patient on a treadmill under standardized conditions. The patient continues the test until walking can no longer be tolerated because of claudication symptoms.</description>
        <time_frame>Assessed at baseline and 3 months</time_frame>
        <population>Participants who had available analyzable baseline, 3 month, and 6 month treadmill test results.</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Walking Time (PWT)</title>
          <description>The average change in maximum time (in minutes) walked by a patient on a treadmill under standardized conditions. The patient continues the test until walking can no longer be tolerated because of claudication symptoms.</description>
          <population>Participants who had available analyzable baseline, 3 month, and 6 month treadmill test results.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="4.4"/>
                    <measurement group_id="O2" value="6.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Artery Questionnaire (PAQ)</title>
        <description>The Peripheral Artery Questionnaire (PAQ) assesses subjective physical limitations, leg symptoms, social function, treatment satisfaction, and quality of life. It is administered as a self report. Higher scores are indicative of better outcome. The summary scores is compiled by taking the mean of five subscales generated from the original questions. Range: Minimum score is 11.1, maximum 85. The measure represents placebo adjusted average change in Peripheral Artery Questionnaire (PAQ) summary score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
        <time_frame>Assessed as a trajectory (baseline, 1mos, 3mos, and 6 mos)</time_frame>
        <population>Participants who had available analyzable baseline, 1 month, 3 month, and 6 month PAQs.</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Artery Questionnaire (PAQ)</title>
          <description>The Peripheral Artery Questionnaire (PAQ) assesses subjective physical limitations, leg symptoms, social function, treatment satisfaction, and quality of life. It is administered as a self report. Higher scores are indicative of better outcome. The summary scores is compiled by taking the mean of five subscales generated from the original questions. Range: Minimum score is 11.1, maximum 85. The measure represents placebo adjusted average change in Peripheral Artery Questionnaire (PAQ) summary score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
          <population>Participants who had available analyzable baseline, 1 month, 3 month, and 6 month PAQs.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="21.5"/>
                    <measurement group_id="O2" value="55.2" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire (WIQ)-Walking Distance Score</title>
        <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0.2, maximum 100. The measure represents the placebo adjusted average change in WIQ walking distance score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
        <time_frame>Assessed as a trajectory (baseline, 1mos, 3mos, and 6 mos)</time_frame>
        <population>Participants who had available analyzable baseline, 1 month, 3 month, and 6 month WIQs.</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Impairment Questionnaire (WIQ)-Walking Distance Score</title>
          <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0.2, maximum 100. The measure represents the placebo adjusted average change in WIQ walking distance score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
          <population>Participants who had available analyzable baseline, 1 month, 3 month, and 6 month WIQs.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="30.1"/>
                    <measurement group_id="O2" value="23.0" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.626</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire (WIQ)- Walking Speed Score</title>
        <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0, maximum 87. The measure represents the placebo adjusted average change in WIQ walking speed score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
        <time_frame>Assessed as a trajectory (baseline, 1mos, 3mos, and 6 mos)</time_frame>
        <population>Participants who had available analyzable baseline, 1 month, 3 month, and 6 month WIQs</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Impairment Questionnaire (WIQ)- Walking Speed Score</title>
          <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0, maximum 87. The measure represents the placebo adjusted average change in WIQ walking speed score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
          <population>Participants who had available analyzable baseline, 1 month, 3 month, and 6 month WIQs</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="20.7"/>
                    <measurement group_id="O2" value="41.8" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.591</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire (WIQ)-Ability to Climb Stairs Score</title>
        <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0, maximum 100. The measure represents the placebo adjusted average change in WIQ ability to climb stairs score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
        <time_frame>Assessed as a trajectory (baseline, 1mos, 3mos, and 6 mos)</time_frame>
        <population>Participants who had available analyzable baseline, 1 month, 3 month, and 6 month WIQs</population>
        <group_list>
          <group group_id="O1">
            <title>ALDHbr</title>
            <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Vehicle)</title>
            <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Impairment Questionnaire (WIQ)-Ability to Climb Stairs Score</title>
          <description>The Walking Impairment Questionnaire (WIQ) assesses the severity of the subjective walking impairment on distance, speed, and stair climbing scales. It is administered as a self report. Range: Minimum score is 0, maximum 100. The measure represents the placebo adjusted average change in WIQ ability to climb stairs score assessed over time. The reported value is the estimate from regression analysis of the slope of the placebo adjusted measure over the time course of the trial adjusted for baseline weight.</description>
          <population>Participants who had available analyzable baseline, 1 month, 3 month, and 6 month WIQs</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" spread="29.9"/>
                    <measurement group_id="O2" value="43.8" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.722</p_value>
            <p_value_desc>Threshold 0.05; no adjustment for multiple comparisons per protocol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events reported are from randomization date to the 6 month endpoint data collection window (i.e 210 days post intervention)</time_frame>
      <desc>Events were assessed systematically at each study visit during the physical exam assessment. A standard workbook was used to collect event details. Sponsor safety team reviewed events and requested additional documentation as needed.</desc>
      <group_list>
        <group group_id="E1">
          <title>ALDHbr</title>
          <description>Participants will receive ALDHbr cells via intramuscular injection
ALDHbr: Ten 1ml injections of ALDHbr cells in the index calf and posterior, lower thigh</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Vehicle)</title>
          <description>Participants will receive placebo (vehicle) via intramuscular injection
Placebo (vehicle): Ten 1ml injections of placebo in the index calf and posterior, lower thigh</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Anginal discomfort (symptomatic)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression of fractured vertebra</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Post procedural hematoma (left popliteal)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Motor vehicle accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CABG</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic limb pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Peripheral arterial disease (worsening)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post operative hip pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial paralysis (Bell's palsy)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size. Only follow up to 6 months. Limitation in the cell dose.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lemuel Moye, MD, PhD</name_or_title>
      <organization>UT-Houston School of Public Health</organization>
      <phone>713-500-9518</phone>
      <email>lemmoye@msn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

